Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 32
Filter
1.
Liver Int ; 39(2): 290-298, 2019 02.
Article in English | MEDLINE | ID: mdl-30248224

ABSTRACT

BACKGROUND: Current guidelines favour the use of bleeding stents over balloon tamponade (BT) for refractory variceal bleeding (VB) from oesophageal varices. However, data on the efficacy and safety of self-expandable metal SX-ELLA Danis stents (SEMS) are limited. METHODS: Cirrhotic patients receiving SEMS for VB at four tertiary care centres were included in this retrospective multicentre study. Rates of failure-to-control bleeding (within 5 days) and bleeding-related mortality (6 weeks) were assessed. RESULTS: SEMS controlled VB in 79.4% (27/34) of patients. In the rest of patients, other rescue treatments including endoscopic band ligation (EBL, n = 3), SEMS renewed (n = 2) or Linton (n = 2) were applied; however, VB was only controlled in one patient. Early rebleeding within six weeks occurred in 17.6% (6/34) patients. Median SEMS dwell time was three (IQR:6) days. Overall n = 13/34 (38.2%) patients died with SEMS in situ. After SEMS removal, rebleeding and bleeding-related death occurred in n = 7 (35%) and n = 5 (14.7%) patients respectively. Only 32.4% (10/34) patients did not experience any rebleeding within six weeks after SEMS removal. Bleeding-related mortality was 47.1% (n = 16/34) and the median survival after SEMS placement was 2.1 months. Notably, no patient received an early transjugular intrahepatic portosystemic shunt (TIPS). The most common adverse events were stent dislocations (n = 13; 38.2%), while ulcers/necrosis of the oesophageal mucosa was seen in only four (11.8%) patients. CONCLUSION: SEMS controlled refractory VB in most patients. However, bleeding-related mortality remained high. While SEMS dislocations were frequent, ulcers/necrosis of the oesophagus was rare. Further studies should investigate whether the wider use of early TIPS reduces bleeding-related mortality after SEMS placement.


Subject(s)
Esophageal and Gastric Varices/therapy , Gastrointestinal Hemorrhage/therapy , Liver Cirrhosis/complications , Stents/adverse effects , Adult , Aged , Austria , Endoscopy, Gastrointestinal , Esophageal and Gastric Varices/etiology , Esophageal and Gastric Varices/mortality , Female , Gastrointestinal Hemorrhage/etiology , Gastrointestinal Hemorrhage/mortality , Humans , Male , Middle Aged , Portasystemic Shunt, Transjugular Intrahepatic , Retrospective Studies , Treatment Outcome
2.
Z Gastroenterol ; 55(1): 75-82, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27723911

ABSTRACT

D-lactic acidosis is a rare complication that occurs mainly in patients with malabsorption due to a surgically altered gastrointestinal tract anatomy, namely in short bowel syndrome or after bariatric surgery. It is characterized by rapid development of neurological symptoms and severe metabolic acidosis, often with a high serum anion gap. Malabsorbed carbohydrates can be fermented by colonic microbiota capable of producing D-lactic acid. Routine clinical assessment of serum lactate covers only L-lactic acid; when clinical suspicion for D-lactic acidosis is high, special assays for D-lactic acid are called for. A serum level of more than 3 mmol/L of D-lactate confirms the diagnosis. Management includes correction of metabolic acidosis by intravenous bicarbonate, restriction of carbohydrates or fasting, and antibiotics to eliminate intestinal bacteria that produce D-lactic acid. We report a case of D-lactic acidosis in a patient with short bowel syndrome and review the pathophysiology of D-lactic acidosis with its biochemical and clinical features. D-lactic acidosis should be considered when patients with short bowel syndrome or other malabsorption syndromes due to an altered gastrointestinal tract anatomy present with metabolic acidosis and neurological symptoms that cannot be attributed to other causes. With the growing popularity of bariatric surgery, this metabolic derangement may be seen more frequently in the future.


Subject(s)
Acidosis, Lactic/diagnosis , Acidosis, Lactic/therapy , Gastric Bypass/adverse effects , Short Bowel Syndrome/etiology , Acidosis, Lactic/etiology , Anti-Bacterial Agents/administration & dosage , Bicarbonates/administration & dosage , Combined Modality Therapy/methods , Diet Therapy/methods , Female , Humans , Middle Aged , Short Bowel Syndrome/diagnosis , Short Bowel Syndrome/therapy , Treatment Outcome
3.
Thromb Res ; 135(3): 485-91, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25613927

ABSTRACT

INTRODUCTION: Prothrombin complex concentrates (PCCs) are a common treatment option for the reversal of oral anticoagulation with vitamin K antagonists (VKAs). This study assessed efficacy and safety of Prothromplex Total®. MATERIALS AND METHODS: Patients (≥18 years) with acquired prothrombin complex coagulation factor deficiency (international normalized ratio [INR] ≥ 2 at screening) due to oral VKAs, requiring reversal of anticoagulation, were treated with 25, 35, or 50 IU/kg BW PCC. After infusion, efficacy was assessed for 72 ± 4 hours. Adverse events (AEs) were captured for 15 days. RESULTS: Sixty-one subjects, 48 requiring interventional procedures and 13 with acute bleeds, received a single infusion of PCC. Of 59 subjects analyzed, all achieved normalization of INR (≤ 1.3) within 30 ± 5 minutes of infusion, demonstrating effective anticoagulant reversal. IVRs of factors II, VII, IX, and X ranged from 1.12-2.03 IU/dL:IU/kg. Median INRs remained between 1.00 and 1.18 for up to 6 hours. Overall efficacy of treatment was rated "excellent" for 60 subjects. Three AEs were deemed possibly related to treatment: 1 serious AE (SAE) of acute myocardial infarction (rated severe), 1 SAE of deep vein thrombosis (rated mild), and 1 AE of pyrexia (rated mild). Thrombotic adverse events (2/61, 3.3%) reported here are comparable to rates observed in other PCC studies. CONCLUSIONS: While there is a risk of thromboembolic events following treatment with PCC products, the number of events reported here was low and could have occurred without PCC treatment. The individualized, INR-based dosing of PCC used here for VKA anticoagulant reversal produces rapid normalization of INR to ≤ 1.3 within 30 minutes.


Subject(s)
Anticoagulants/therapeutic use , Blood Coagulation Factors/therapeutic use , Hemostatics/therapeutic use , Vitamin K/antagonists & inhibitors , Adult , Aged , Aged, 80 and over , Anticoagulants/adverse effects , Blood Coagulation Factors/adverse effects , Female , Hemorrhage/chemically induced , Hemorrhage/prevention & control , Hemostatics/adverse effects , Humans , International Normalized Ratio , Male , Middle Aged , Prospective Studies
4.
Surg Endosc ; 28(3): 854-60, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24196547

ABSTRACT

BACKGROUND: Biliary radiofrequency ablation (RFA) using the Habib™ EndoHBP catheter is a new endoscopic palliation therapy for malignant biliary obstruction. The aim of this study was to assess the feasibility and safety of this technique. METHODS: In this nationwide retrospective study of prospectively collected clinical data, all patients treated by biliary RFA in Austria between November 2010 and December 2012 were included. Procedure-related complications, adverse events within 30 days post-intervention, stent patency, and mortality rates were investigated. RESULTS: A total of 58 patients (31 male, 27 female, median age 75 years) underwent 84 RFA procedures at 11 Austrian referral centers for biliary endoscopy. The predominant underlying condition was Klatskin tumor (45 of 58 cases). All 84 RFA procedures were feasible without technical problems. A partial liver infarction was induced by RFA in a 49-year-old Klatskin tumor patient. During 30 days after each RFA procedure, five cases of cholangitis, three cases of hemobilia, two cases of cholangiosepsis, and one case each of gallbladder empyema, hepatic coma, and newly diagnosed left bundle branch block occurred. Median stent patency after last electively performed RFA was 170 days (95 % CI 63-277) and was almost significantly different between metal and plastic stenting (218 vs. 115 days; p = 0.051). Median survival was 10.6 months (95 % CI 6.9-14.4) from the time of the first RFA in each patient and 17.9 months (95 % CI 10.3-25.6) from the time of initial diagnosis. CONCLUSIONS: Except for one severe interventional complication (hepatic infarct), RFA presented as a technically feasible and safe therapeutic option for the palliative treatment of malignant biliary obstruction. The good results of stent patency and survival in this study should be proven in prospective (controlled) trials to further quantify the efficacy of this promising new technique.


Subject(s)
Bile Duct Neoplasms/complications , Catheter Ablation/instrumentation , Cholangiopancreatography, Endoscopic Retrograde/methods , Cholestasis/surgery , Surgery, Computer-Assisted/methods , Adult , Aged , Aged, 80 and over , Animals , Austria/epidemiology , Bile Duct Neoplasms/diagnosis , Cats , Cholestasis/diagnosis , Cholestasis/etiology , Equipment Design , Female , Follow-Up Studies , Humans , Incidence , Male , Middle Aged , Palliative Care/methods , Postoperative Complications/epidemiology , Retrospective Studies , Stents , Survival Rate/trends , Time Factors
5.
Intensive Care Med ; 39(7): 1227-37, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23636826

ABSTRACT

PURPOSE: Increased arterial ammonia levels are associated with high mortality in patients with acute liver failure (ALF). Data on the prognostic impact of arterial ammonia is lacking in hypoxic hepatitis (HH) and scarce in critically ill patients with cirrhosis. METHODS: The patient cohort comprised 72 patients with HH, 43 patients with ALF, 100 patients with liver cirrhosis and 45 patients without evidence for liver disease. Arterial ammonia concentrations were assessed on a daily basis in all patients and the results were compared among these four patient groups and between 28-day survivors and 28-day non-survivors overall and in each group. RESULTS: Overall 28-day mortality rates in patients with HH, ALF and cirrhosis and in the control group were 54, 30, 49 and 27 %, respectively. Peak arterial ammonia levels differed significantly between transplant-free 28-day survivors and non-survivors in the HH and ALF groups (p < 0.01 for both). Multivariate regression identified peak arterial ammonia concentrations as an independent predictor of 28-day mortality or liver transplantation in patients with HH and ALF, respectively (p < 0.01). There was no association between mortality and arterial ammonia in patients with liver cirrhosis and in the control group. Admission arterial ammonia levels were independently linked to hepatic encephalopathy grades 3/4 in patients with HH (p < 0.01), ALF (p < 0.05) and cirrhosis (p < 0.05), respectively. CONCLUSIONS: Elevated arterial ammonia levels indicate a poor prognosis in acute liver injury and are associated with advanced HE in HH, ALF and cirrhosis. Arterial ammonia levels provide additional information in the risk assessment of critically ill patients with liver disease.


Subject(s)
Ammonia/blood , Hepatitis/mortality , Liver Cirrhosis/mortality , Liver Failure, Acute/mortality , Adult , Aged , Austria/epidemiology , Biomarkers/blood , Case-Control Studies , Disease-Free Survival , Female , Hepatitis/diagnosis , Humans , Liver Cirrhosis/diagnosis , Liver Failure, Acute/diagnosis , Logistic Models , Male , Middle Aged , Multivariate Analysis , Prognosis , Prospective Studies
6.
Wien Klin Wochenschr ; 125(7-8): 200-19, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23579878

ABSTRACT

In November 2004, the Austrian Society of Gastroenterology and Hepatology (ÖGGH) held for the first time a consensus meeting on the definitions and treatment of portal hypertension and its complications in the Billroth-Haus in Vienna, Austria (Billroth I-Meeting). This meeting was preceded by a meeting of international experts on portal hypertension with some of the proponents of the Baveno consensus conferences (http://www.oeggh.at/videos.asp). The consensus itself is based on the Baveno III consensus with regard to portal hypertensive bleeding and the suggestions of the International Ascites Club regarding the treatment of ascites. Those statements were modified by new knowledge derived from the recent literature and also by the current practice of medicine as agreed upon by the participants of the consensus meeting. In October 2011, the ÖGGH organized the second consensus meeting on portal hypertension and its complications in Vienna (Billroth II-Meeting). The Billroth II-Guidelines on the definitions and treatment of portal hypertension and its complications take into account the developments of the last 7 years, including the Baveno-V update and several key publications.


Subject(s)
Esophageal and Gastric Varices/diagnosis , Esophageal and Gastric Varices/therapy , Gastroenterology/standards , Gastrointestinal Hemorrhage/diagnosis , Gastrointestinal Hemorrhage/therapy , Hypertension, Portal/diagnosis , Hypertension, Portal/therapy , Esophageal and Gastric Varices/etiology , Gastrointestinal Hemorrhage/etiology , Humans , Hypertension, Portal/complications
7.
Gut ; 62(11): 1634-41, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23250049

ABSTRACT

OBJECTIVE: Non-selective ß-blockers or endoscopic band ligation (EBL) are recommended for primary prophylaxis of variceal bleeding in patients with oesophageal varices. Additional α-adrenergic blockade (as by carvedilol) may increase the number of patients with haemodynamic response (reduction in hepatic venous pressure gradient (HVPG) of ≥ 20% or to values <12 mm Hg). DESIGN: Patients with oesophageal varices undergoing measurement of HVPG before and under propranolol treatment (80-160 mg/day) were included. HVPG responders were kept on propranolol (PROP group), while non-responders were placed on carvedilol (6.25-50 mg/day). Carvedilol responders continued treatment (CARV group), while non-responders to carvedilol underwent EBL. The primary aim was to assess haemodynamic response rates to carvedilol in propranolol non-responders. RESULTS: 36% (37/104) of patients showed a HVPG response to propranolol. Among the propranolol non-responders 56% (38/67) eventually achieved a haemodynamic response with carvedilol, while 44% (29/67) patients were finally treated with EBL. The decrease in HVPG was significantly greater with carvedilol (median 12.5 mg/day) than with propranolol (median 100 mg/day): -19 ± 10% versus -12 ± 11% (p<0.001). During a 2 year follow-up bleeding rates for PROP were 11% versus CARV 5% versus EBL 25% (p=0.0429). Fewer episodes of hepatic decompensation (PROP 38%/CARV 26% vs EBL 55%; p=0.0789) and significantly lower mortality (PROP 14%/CARV 11% vs EBL 31%; p=0.0455) were observed in haemodynamic responders compared to the EBL group. CONCLUSIONS: Carvedilol leads to a significantly greater decrease in HVPG than propranolol. Using carvedilol for primary prophylaxis a substantial proportion of non-responders to propranolol can achieve a haemodynamic response, which is associated with improved outcome with regard to prevention of variceal bleeding, hepatic decompensation and death.


Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Carbazoles/therapeutic use , Esophageal and Gastric Varices/prevention & control , Gastrointestinal Hemorrhage/prevention & control , Liver Cirrhosis/complications , Propanolamines/therapeutic use , Adrenergic beta-Antagonists/administration & dosage , Adult , Aged , Carbazoles/administration & dosage , Carvedilol , Dose-Response Relationship, Drug , Esophageal and Gastric Varices/etiology , Esophageal and Gastric Varices/physiopathology , Female , Follow-Up Studies , Gastrointestinal Hemorrhage/etiology , Gastrointestinal Hemorrhage/physiopathology , Hemodynamics/drug effects , Humans , Kaplan-Meier Estimate , Ligation , Liver Cirrhosis/physiopathology , Male , Middle Aged , Propanolamines/administration & dosage , Propranolol/therapeutic use , Treatment Failure , Treatment Outcome
8.
Hepatology ; 57(3): 1153-62, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23213075

ABSTRACT

UNLABELLED: Acute-on-chronic liver failure (ACLF) is a frequent cause of death in cirrhosis. Albumin dialysis with the molecular adsorbent recirculating system (MARS) decreases retained substances and improves hemodynamics and hepatic encephalopathy (HE). However, its survival impact is unknown. In all, 189 patients with ACLF were randomized either to MARS (n=95) or to standard therapy (SMT) (n=94). Ten patients (five per group) were excluded due to protocol violations. In addition, 23 patients (MARS: 19; SMT: 4) were excluded from per-protocol (PP) analysis (PP population n=156). Up to 10 6-8-hour MARS sessions were scheduled. The main endpoint was 28-day ITT and PP survival. There were no significant differences at inclusion, although the proportion of patients with Model for Endstage Liver Disease (MELD) score over 20 points and with spontaneous bacterial peritonitis (SBP) as a precipitating event was almost significantly greater in the MARS group. The 28-day survival was similar in the two groups in the ITT and PP populations (60.7% versus 58.9%; 60% versus 59.2% respectively). After adjusting for confounders, a significant beneficial effect of MARS on survival was not observed (odds ratio [OR]: 0.87, 95% confidence interval [CI] 0.44-1.72). MELD score and HE at admission and the increase in serum bilirubin at day 4 were independent predictors of death. At day 4, a greater decrease in serum creatinine (P=0.02) and bilirubin (P=0.001) and a more frequent improvement in HE (from grade II-IV to grade 0-I; 62.5% versus 38.2%; P=0.07) was observed in the MARS group. Severe adverse events were similar. CONCLUSION: At scheduled doses, a beneficial effect on survival of MARS therapy in patients with ACLF could not be demonstrated. However, MARS has an acceptable safety profile, has significant dialysis effect, and nonsignificantly improves severe HE.


Subject(s)
End Stage Liver Disease/therapy , Liver Failure, Acute/therapy , Serum Albumin/metabolism , Sorption Detoxification/methods , Adult , End Stage Liver Disease/mortality , Female , Hospitalization/statistics & numerical data , Humans , Liver Cirrhosis/mortality , Liver Cirrhosis/therapy , Liver Failure, Acute/mortality , Logistic Models , Male , Middle Aged , Multiple Organ Failure/mortality , Multiple Organ Failure/therapy , Multivariate Analysis , Peritonitis/mortality , Peritonitis/therapy , Prospective Studies , Renal Dialysis/adverse effects , Renal Dialysis/methods , Sorption Detoxification/adverse effects , Sorption Detoxification/mortality , Treatment Outcome
9.
Liver Int ; 31 Suppl 3: 1-4, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21824274

ABSTRACT

Acute liver failure (ALF) is a dramatic clinical syndrome with high mortality because of cerebral oedema (type A hepatic encephalopathy) and multi-organ failure. With intensive care medicine and emergent liver transplantation being the mainstay of treatment, alternatives to transplantation are increasingly needed. Ammonia has been recognised as a major toxin in patients with ALF. It can be effectively removed by haemodialysis, haemofiltration and artificial liver support (a combination of extracorporeal toxin absorption and haemodialysis). Previous studies of extracorporeal detoxification, however, have either not specifically targeted ammonia or were hampered by poor biocompatibility and obsolete pathophysiological assumptions, ultimately failing to improve the prognosis. Moreover, most patients were treated only late after the emergence of advanced HE and multi-organ failure, while detoxification should prevent these complications. Acute-on-chronic liver failure (AOCLF) occurs in the setting of chronic liver disease and has an equally poor prognosis. Here, the goals of extracorporeal blood detoxification are renal support and haemodynamic stabilisation in order to support recompensation. Patients with AOCLF, unfortunately, are at a risk for treatment-related complications including bleeding, thrombocytopenia, hypotension and acute renal failure, making biocompatibility a critical issue. Peritoneal dialysis could possibly emerge as a more biocompatible way of treating refractory hepatorenal syndrome. This article will critically analyse the pathophysiological concepts and goals of extracorporeal detoxification in acute and chronic liver diseases.


Subject(s)
Ammonia/blood , Brain Edema/prevention & control , Extracorporeal Circulation , Hepatic Encephalopathy/prevention & control , Liver Failure, Acute/complications , Liver Failure, Acute/therapy , Sorption Detoxification/methods , Ammonia/isolation & purification , Ammonia/toxicity , Brain Edema/etiology , Hepatic Encephalopathy/etiology , Humans , Liver Failure, Acute/physiopathology , Liver, Artificial , Peritoneal Dialysis/instrumentation , Peritoneal Dialysis/methods
10.
Anasthesiol Intensivmed Notfallmed Schmerzther ; 45(11-12): 696-706, 2010 Nov.
Article in German | MEDLINE | ID: mdl-21120767

ABSTRACT

Maintaining regular function of the intestinal tract is an important prerequisite for successful outcomes in critical illness. Disturbances of gastrointestinal motility are frequently caused by drugs, excessive fluid load, mechanical ventilation, surgical or ischemic damage, and occur frequently in sepsis and SIRS. Impaired gastrointestinal motility may give rise to a vitious circle of enteral nutrition intolerance, edema, and may eventually result in a breakdown of the gastrointestinal barrier. Early diagnosis, patient-adapted treatment and a focus on prophylactic measures are necessary prerequisites to maintain gut function in critically ill patients.


Subject(s)
Gastrointestinal Diseases/physiopathology , Gastrointestinal Motility/physiology , Intensive Care Units , Critical Care , Edema/complications , Endoscopy, Gastrointestinal , Enteral Nutrition/adverse effects , Fluid Therapy/adverse effects , Gastrointestinal Diseases/diagnosis , Gastrointestinal Diseases/etiology , Gastrointestinal Diseases/therapy , Gastrointestinal Motility/drug effects , Humans , Ischemia/complications , Ischemia/physiopathology , Postoperative Complications/physiopathology , Respiration, Artificial/adverse effects , Sepsis/complications , Sepsis/physiopathology
11.
Wien Klin Wochenschr ; 122(7-8): 203-18, 2010 Apr.
Article in German | MEDLINE | ID: mdl-20503019

ABSTRACT

Increasing life expectancy results in an increased number of elderly cancer patients. Comorbidities and functional impairment influence the patient's course of disease and the choice of antineoplastic treatment. The Comprehensive Geriatric Assessment (CGA) supports the appraisal of the patient's individual health characteristics, especially due to the fact that chronologic age does not always correlate with the patient's health. Next to the appraisal of comorbidities and functional impairment, nutritional state, cognitive impairment, psychological state, social support, quality of life and the patient's medication are recorded. The Society of Geriatric Oncology (SIOG) recommends the CGA in cancer patients older than seventy years. While planning a systemic antineoplastic therapy, renal, hepatic, cardiac and bone marrow insufficiencies have to be considered. Renal and hepatic impairment often cause in dose reduced antineoplastic treatment, whereas in patients with cardiac insufficiency liposomale substances and in patients with decreased bone marrow function growth factors are available. Additionally to the oncological treatment, an early involvement of palliative care specialists should be considered.


Subject(s)
Geriatric Assessment , Neoplasms/epidemiology , Age Factors , Aged , Antineoplastic Agents/therapeutic use , Antineoplastic Agents/toxicity , Comorbidity , Cooperative Behavior , Health Status Indicators , Humans , Interdisciplinary Communication , Neoplasms/diagnosis , Neoplasms/drug therapy , Prognosis
12.
Clin Gastroenterol Hepatol ; 7(9): 1000-6, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19465152

ABSTRACT

BACKGROUND & AIMS: Ionized ammonia (NH(3)) and partial pressure of the gaseous ammonia (pNH(3)) are associated with hepatic encephalopathy and intracranial hypertension in patients with acute liver failure; NH(3) is also believed to contribute to extrahepatic organ failure. We investigated whether the severity of organ failure was associated with intracranial hypertension and evaluated the correlation between NH(3) and pNH(3) and grade of hepatic encephalopathy. METHODS: In 87 patients with acute liver failure admitted to the intensive care unit, we simultaneously evaluated arterial ammonia, pNH(3), clinical grade of hepatic encephalopathy, the sequential organ failure assessment score (SOFA score), and evidence of intracranial hypertension. RESULTS: In comparing patients with intracranial hypertension (n = 37) with patients without intracranial hypertension (n = 50), the highest NH(3) and pNH(3) levels and SOFA scores before onset of intracranial hypertension were independent predictors of intracranial hypertension (P < .001). Among patients with NH(3) levels less than 146 mumol/L, those with intracranial hypertension had a higher SOFA score than those without intracranial hypertension (median, 10 vs 5.5; P = .004), despite the patients' similar levels of NH(3). NH(3) (r = 0.68, P < .0001) and pNH(3) (r = 0.78, P < .0001) both correlated with grade of hepatic encephalopathy. However, in multiple regression analysis, only pNH(3) (P < .0001) was shown to be a significant independent parameter for predicting grade of hepatic encephalopathy (P = .27). CONCLUSIONS: SOFA score and ammonia levels are independent predictors of intracranial hypertension. In patients with acute liver failure admitted to the intensive care unit, pNH(3) level is a better predictor of clinical grade of hepatic encephalopathy than arterial NH(3) level.


Subject(s)
Ammonia/blood , Hepatic Encephalopathy/physiopathology , Intracranial Hypertension/physiopathology , Liver Failure, Acute/complications , Multiple Organ Failure/physiopathology , APACHE , Adult , Ammonia/toxicity , Female , Hepatic Encephalopathy/blood , Hepatic Encephalopathy/etiology , Humans , Intensive Care Units/statistics & numerical data , Intracranial Hypertension/blood , Intracranial Hypertension/etiology , Liver Failure, Acute/blood , Liver Failure, Acute/physiopathology , Male , Middle Aged , Partial Pressure , Predictive Value of Tests , Risk Factors , Severity of Illness Index , Young Adult
13.
Nephrol Dial Transplant ; 23(11): 3501-8, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18723567

ABSTRACT

BACKGROUND: Hypernatraemia is common in intensive care patients and may present an independent risk factor of mortality. Several formulae have been proposed to guide infusion therapy for correction of serum sodium. Unfortunately, these formulae have never been validated comparatively. We assessed the predictive potential of four different formulae (Adrogué-Madias, Barsoum-Levine, Kurtz-Nguyen and a simple formula based on electrolyte-free water clearance) in correction and maintenance of serum sodium in 66 hyper- and normonatraemic ICU patients. METHODS: With daily measurements of sodium/potassium and fluid/electrolyte balances, a day-to-day prediction of serum sodium levels was calculated using the four formulae. This was compared to the measured changes in serum sodium. RESULTS: Six hundred and eighty-one patient-days (194 hypernatraemic) in 66 patients were available for calculations. Prediction of serum sodium levels using all four formulae correlated significantly (P < 0.05) with measured changes in serum sodium. Individual variations were extreme, and the mean differences (+/-SD) for predicted versus measured serum sodium were within the range of 3.4-4.5 (+/-4.4-4.7) mmol/l similar for the Adrogué-Madias, Barsoum-Levine and Nguyen-Kurtz formulae. In comparison, our proposed formula underestimated the changes of serum sodium (mean +/- SD -1.5 +/- 5.3). During hypernatraemia, the differences between predicted and measured values were even greater (mean +/- SD 5.0-6.7 +/- 3.9-4.3) using the published formulae compared to our formula (mean +/- SD 0.2 +/- 4.0). CONCLUSIONS: Currently available formulae to guide infusion therapy in hyper- and normonatraemic states do not accurately predict changes of serum sodium in the individual ICU patient. In clinical practice, infusion therapy should be based on the reasons for hypernatraemia and serial measurements of serum sodium to avoid evolution of derangements.


Subject(s)
Hypernatremia/blood , Models, Biological , Sodium/blood , Adult , Aged , Critical Care , Female , Humans , Male , Middle Aged , Predictive Value of Tests , Retrospective Studies , Water-Electrolyte Balance
14.
Hepatology ; 46(6): 1682-4, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18046718
15.
Am J Kidney Dis ; 50(6): 952-7, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18037096

ABSTRACT

BACKGROUND: Hypernatremia is common in the intensive care unit (ICU). We assessed the prevalence of hypernatremia and its impact on mortality and ICU length of stay (LOS). STUDY DESIGN: Retrospective analysis. SETTING & PARTICIPANTS: All patients admitted to a medical ICU of a university hospital during a 35-month observation period. PREDICTOR: Hypernatremia (serum sodium > 149 mmol/L) after admission to the ICU. OUTCOMES & MEASUREMENTS: Main outcomes were 28-day hospital mortality and ICU LOS. Demographic factors, main diagnosis, and severity of illness. Cox proportional hazards regression models were used for data analysis. RESULTS: Of 981 patients, 90 (9%) had hypernatremia, on admission to the ICU in 21 (2%) and developed during the ICU stay in 69 patients (7%). Of these 981 patients, 235 (24%) died; LOS was 8 +/- 9 (SD) days. Mortality rates were 39% and 43% in patients with hypernatremia on admission or that developed after admission compared with 24% in patients without hypernatremia (P < 0.01). LOS was 20 +/- 16 days in patients with hypernatremia compared with 8 +/- 10 days in patients without hypernatremia (P < 0.001). In multivariable analysis, hypernatremia was an independent risk factor for mortality (relative risk, 2.1; 95% confidence interval, 1.4 to 3.3). LIMITATIONS: Retrospective design, absence of data for long-term mortality. CONCLUSIONS: Most cases of hypernatremia in the ICU developed after admission, suggesting an iatrogenic component in its evolution. Hypernatremia is associated with increased mortality. Strategies for preventing hypernatremia in the ICU should be encouraged.


Subject(s)
Critical Illness/mortality , Hospital Mortality , Hypernatremia/diagnosis , Hypernatremia/etiology , Adult , Aged , Female , Humans , Intensive Care Units , Kaplan-Meier Estimate , Length of Stay/statistics & numerical data , Male , Middle Aged , Multivariate Analysis , Prevalence , Prognosis , Proportional Hazards Models , Retrospective Studies , Risk Factors
16.
Crit Care Med ; 35(4): 1099-104, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17334250

ABSTRACT

OBJECTIVE: In critically ill patients, hepatic dysfunction is regarded as a late organ failure associated with poor prognosis. We investigated the incidence and prognostic implications of early hepatic dysfunction (serum bilirubin >2 mg/dL within 48 hrs of admission). DESIGN: Prospective, multicenter cohort study. SETTING: Thirty-two medical, surgical, and mixed intensive care units. PATIENTS: A total of 38,036 adult patients admitted consecutively over a period of 4 yrs. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Excluding patients with preexisting cirrhosis (n = 691; 1.8%) and acute or acute-on-chronic hepatic failure (n = 108, 0.3%), we identified 4,146 patients (10.9%) with early hepatic dysfunction. These patients had different baseline characteristics, longer median intensive care unit stays (5 vs. 3 days; p < .001) and increased hospital mortality (30.4% vs. 16.4%; p < .001). Hepatic dysfunction was also associated with higher observed-to-expected mortality ratios (1.02 vs. 0.91; p < .001). Multiple logistic regression analysis showed an independent mortality risk of hepatic dysfunction (odds ratio, 1.86; 95% confidence interval, 1.71-2.03; p < .001), which exceeded the impact of all other organ dysfunctions. A case-control study further confirmed these results: Patients with early hepatic dysfunction exhibited significantly increased raw and risk-adjusted mortality compared with control subjects. CONCLUSIONS: Our results provide strong evidence that early hepatic dysfunction, occurring in 11% of critically ill patients, presents a specific and independent risk factor for poor prognosis.


Subject(s)
Critical Illness/epidemiology , Liver Diseases/diagnosis , Liver Diseases/epidemiology , Case-Control Studies , Critical Illness/mortality , Female , Hospital Mortality , Humans , Incidence , Length of Stay/statistics & numerical data , Male , Middle Aged , Outcome Assessment, Health Care/statistics & numerical data , Prognosis , Prospective Studies , Risk Assessment
17.
AIDS ; 19 Suppl 3: S85-92, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16251834

ABSTRACT

OBJECTIVES: To assess the relative impact of fatigue and subclinical cognitive brain dysfunction on the impairment of health-related quality of life (HRQL) in hepatitis C virus (HCV) infection. DESIGN AND METHODS: We performed a cross-sectional study in 120 patients with untreated chronic HCV infection to test the hypothesis that the severity of fatigue had an independent effect on HCV-associated impairment of HRQL. Patients were investigated using the short-form-36 questionnaire, the fatigue impact scale, the brief fatigue inventory, and P300 event-related potentials, as an objective correlate of neurocognitive function. Patients with decompensated cirrhosis or clinical depression were excluded. RESULTS: Relative to healthy controls, HCV-infected patients showed significant levels of fatigue (Fatigue Impact Scale, 49 versus 26 points, brief fatigue inventory, 3.0 versus 1.6 points, P < 0.001). Fatigue impact scale and brief fatigue inventory scores were highly correlated (r = 0.77, P < 0.001), demonstrating concurrent validity. Severity of fatigue and age were the only factors independently associated with the impairment of HRQL (P < 0.001). Fatigue was not related to the severity of hepatitis or the degree of subclinical brain dysfunction. CONCLUSION: In untreated patients with chronic HCV infection, fatigue severity and age but not neurocognitive dysfunction or hepatic function are independently associated with impaired HRQL. Both the fatigue impact scale and the brief fatigue inventory are suitable tools to assess the subjective burden of fatigue. Our findings stress the need for effective therapeutic interventions to reduce the burden of fatigue in patients with HCV infection.


Subject(s)
Cognition Disorders/virology , Fatigue/virology , Hepatitis C, Chronic/complications , Quality of Life , Adult , Age Factors , Aged , Cognition Disorders/rehabilitation , Cross-Sectional Studies , Event-Related Potentials, P300 , Fatigue/rehabilitation , Female , Health Status Indicators , Hepatitis C, Chronic/psychology , Hepatitis C, Chronic/rehabilitation , Humans , Male , Middle Aged , Psychometrics , Severity of Illness Index
18.
Crit Care Med ; 33(7): 1492-8, 2005 Jul.
Article in English | MEDLINE | ID: mdl-16003053

ABSTRACT

OBJECTIVE: To test whether real-time polymerase chain reaction allows for rapid quantitative detection of Streptococcus pneumoniae, Chlamydia pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila in bronchoalveolar lavage fluids and to determine the prevalence of these pathogens in nosocomial ventilator-associated pneumonia. DESIGN: Prospective epidemiologic study applying a new molecular biology-based diagnostic tool during a 27-month period. SETTING: Three medical intensive care units of a tertiary care university hospital. PATIENTS: One hundred patients suffering from nosocomial ventilator-associated pneumonia, hospitalized for > or =14 days, intubated for reasons other than pneumonia, and mechanically ventilated for >48 hrs. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: S. pneumoniae, M. pneumoniae, and C. pneumoniae were detected in bronchoalveolar lavage fluids of 100 patients in 20 (20%), three (3%), and two (2%) cases, respectively. There of 17 (71%) revealed no growth or no significant growth by conventional culture. In one patient, S. pneumoniae and M. pneumoniae were detected simultaneously. Corresponding colony-forming units/mL were partly up to 10 CFU/mL with Gram stainings showing signs of acute inflammation in 80%. A significant temporary correlation between the number of days on ventilator, development of nosocomial pneumonia, and the frequency of detection of these pathogens was found for day 4. CONCLUSIONS: S. pneumoniae, M. pneumoniae, and C. pneumoniae should be considered as causative agents in critically ill patients who develop early-onset nosocomial ventilator-associated pneumonia. Thus, empirical antimicrobial regimens should cover S. pneumoniae, Chlamydia, and Mycoplasma alike. Quantitative polymerase chain reaction is a fast diagnostic tool allowing for detection of these bacteria within 3 hrs in pretreated patients.


Subject(s)
Cross Infection/diagnosis , Cross Infection/etiology , Pneumonia, Bacterial/diagnosis , Pneumonia, Bacterial/etiology , Respiration, Artificial/adverse effects , Adult , Aged , Bronchoalveolar Lavage Fluid/microbiology , Cross Infection/microbiology , Female , Hospital Bed Capacity, 500 and over , Hospitals, Teaching , Humans , Intensive Care Units , Male , Middle Aged , Pneumonia, Bacterial/microbiology , Polymerase Chain Reaction/methods , Prospective Studies
19.
AJR Am J Roentgenol ; 184(2): 505-10, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15671371

ABSTRACT

OBJECTIVE: Our aim was to measure the arterial, portal venous, and total perfusion of the liver parenchyma with dynamic, single-section CT in patients with liver cirrhosis before and after transjugular intrahepatic portosystemic shunt (TIPS) placement and to compare the results with normal values. SUBJECTS AND METHODS: Perfusion of the liver parenchyma was measured in 24 healthy volunteers and 41 patients with liver cirrhosis using dynamic single-section CT. Seventeen patients underwent TIPS placement, and CT measurements were repeated within 7 days. CT scans were obtained at a single level comprising the liver, spleen, aorta, and portal vein. Scans were obtained over a period of 88 sec (one baseline scan followed by 16 scans every 2 sec and eight scans every 7 sec) beginning with the injection of a contrast agent bolus (40 mL at 10 mL/sec). Parenchymal and vascular contrast enhancement was measured with regions of interest, and time-density curves were obtained. These data were processed with a pharmaco-dynamic fitting program (TopFit), and the arterial and portal venous component and the total perfusion of the hepatic parenchyma were calculated (milliliters of perfusion per minute per 100 mL of tissue). RESULTS: Mean normal values for hepatic arterial, portal venous, and total perfusion were 20, 102, and 122 mL/min per 100 mL, respectively. In patients with cirrhosis before TIPS, mean hepatic arterial, portal venous, and total perfusion was 28, 63, and 91 mL/min per 100 mL, respectively, which was statistically significant for all values (p <0.05). After TIPS, hepatic perfusion increased to a mean value of 48, 65, 113 mL/min per 100 mL for arterial (p <0.01), portal venous, and total (p=0.011) perfusion, respectively. CONCLUSION: In patients with cirrhosis, the hepatic arterial perfusion increased, whereas portal venous and total perfusion decreased compared with that of healthy volunteers. TIPS placement caused a statistically significant increase of the hepatic arterial and total hepatic perfusion. The portal venous parenchymal perfusion remained unchanged.


Subject(s)
Liver Circulation/physiology , Liver Cirrhosis/surgery , Portasystemic Shunt, Transjugular Intrahepatic , Tomography, X-Ray Computed , Adult , Aged , Aged, 80 and over , Contrast Media , Female , Humans , Linear Models , Liver Cirrhosis/diagnostic imaging , Male , Middle Aged , Radiography, Interventional , Reference Values
20.
Ann Thorac Surg ; 78(2): 513-8; discussion 518-9, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15276509

ABSTRACT

BACKGROUND: To objectively measure long-term neurocognitive deficit in patients undergoing coronary artery bypass grafting and compare the findings with nonsurgical controls. METHODS: We prospectively measured neurocognitive function in patients undergoing coronary artery bypass grafting (CABG) with cardiopulmonary bypass (n = 104; mean age 64.1 years old; EuroSCORE 2.7 [means]). A cohort of age- and sex-matched patients (n = 80; mean age 63.4 years old) served as nonsurgical controls. After CABG, neurocognitive function was serially reevaluated at 7-day (n = 104), 4-month (n = 100), and 3-year follow-up (n = 88). Neurocognitive function was objectively measured by means of cognitive P300 evoked potentials. Additionally, standard psychometric tests were performed (Trailmaking Test A, Mini Mental State Examination). RESULTS: As compared to preoperative measures (364 +/- 36 ms), cognitive P300 evoked potentials were prolonged (=impaired) at 7-day (381 +/- 36 ms; p = 0.001), 4-month (378 +/- 31 ms; p = 0.08), and 3-year follow-up (379 +/- 35 ms; p = 0.002), respectively. Trailmaking Test A was abnormal, as compared to preoperative, at 3-year follow-up (p < 0.001). Before the operation, surgical patients were fully comparable in P300 measures to nonsurgical controls (363 +/- 32 ms; p = 0.362). Most importantly, throughout the entire postoperative follow-up cognitive measures in surgical patients were prolonged (=impaired) as compared with controls (7-day p = 0.001; 4-month p = 0.002 and 3-year p = 0.003, respectively). In stepwise multivariate regression analysis, neurocognitive deficit at 4-month follow-up (p < 0.001), age (p = 0.012), and persistent atrial fibrillation (p = 0.024) were predictive for long-term neurocognitive deficit at 3-year follow-up. CONCLUSIONS: As shown by means of objective measures, and in comparison to nonsurgical controls, coronary artery bypass grafting with cardiopulmonary bypass grafting causes long-term neurocognitive deficit.


Subject(s)
Brain Damage, Chronic/etiology , Cognition Disorders/etiology , Coronary Artery Bypass/statistics & numerical data , Postoperative Complications/etiology , Aged , Anesthesia, General , Atrial Fibrillation/epidemiology , Atrial Fibrillation/etiology , Atrial Fibrillation/psychology , Brain Damage, Chronic/epidemiology , Cognition Disorders/epidemiology , Cohort Studies , Event-Related Potentials, P300 , Extracorporeal Membrane Oxygenation , Female , Follow-Up Studies , Humans , Male , Middle Aged , Neuropsychological Tests , Postoperative Complications/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...